Climb Bio (NASDAQ:CLYM) Issues Earnings Results, Beats Expectations By $0.02 EPS

Climb Bio (NASDAQ:CLYM) announced its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02, Zacks reports.

Climb Bio Price Performance

CLYM opened at $1.30 on Thursday. The firm has a fifty day moving average price of $1.57. Climb Bio has a 1 year low of $1.20 and a 1 year high of $11.55. The company has a market cap of $87.39 million, a P/E ratio of -0.61 and a beta of -0.19.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CLYM. Leerink Partners began coverage on shares of Climb Bio in a research note on Monday, December 2nd. They set an “outperform” rating and a $10.00 target price for the company. Leerink Partnrs raised shares of Climb Bio to a “strong-buy” rating in a report on Monday, December 2nd.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.